Oct. 19 at 5:03 PM
$LAURUSLABS.NSE
जहाँ विज्ञान है जीवन की सेवा में, वहाँ होता है स्वस्थ भविष्य का निर्माण – Laurus Labs के साथ आप हमेशा सुरक्षित!
Company Overview
$LAURUS Labs is a Hyderabad-based integrated pharmaceutical and biotechnology company, established in 2005. The business is built on three pillars: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and Custom Synthesis/CDMO. Laurus commands leadership in anti-retroviral, oncology, and specialty APIs, supplying to over 70 countries, with 15 globally approved manufacturing facilities. Their portfolio increasingly emphasizes advanced biotech, gene therapy, and specialty chemistry innovation, making the business future-ready for high-margin science-driven expansion.
Financial Performance & Quality
•FY25 Revenues: ₹5,554 Crore (YoY growth 10%).
•Q1 FY26 Revenues: ₹1,580 Crore, 32% YoY growth, indicating robust operational scaling.
•FY25 Net Profit: ₹358 Crore (up 122% YoY; net margin 6.4%).
•Q1 FY26 PAT: ₹161.68 Crore, up 1175% YoY, with EPS at ₹3.0.
•EBITDA (FY25): ₹1,115 Crore (+40% YoY); EBITDA Margin: 20.1% (up 430 bps YoY), supported by improved product mix & asset utilization.
•ROCE: 9.7%, up 330 bps YoY; ROE: 11%.
•R&D Spend: ₹257 Crore (4.6% of revenue), reflecting future-ready innovation; 75+ new projects and peptide, gene therapy diversification.
•Net Debt/EBITDA: 2.3x (improving leverage); Capex: ₹659 Crore FY25; operating cash slightly declined on higher working capital.
•Valuation: P/E 96x TTM, P/B 10.9, P/S 8.19 – at premium, justified if growth/innovation persists.
Business Drivers & Expansion
•
$STRONG performance in the Custom Synthesis/CDMO vertical with growing global contracts.
•ARV business stable; focus on scaling specialty APIs, gene, and cell therapies.
•Strategically deepening$
$RELATIONSHIPS with global innovators and investing in peptide chemistry, biocatalysis, and continuous flow tech.
•JV with Slovenia’s KRKA, new R&D sites, peptide launch & expanded European presence indicate sustained global vision.
Technical Analysis (Oct 2025)
•CMP: ₹900.05
•The
$STOCK is showing momentum recovery after previous consolidation; recent price breakout above moving averages (green/cyan/blue/black/gold lines) confirms bullish undertone.
•Parabolic SAR: Flipped below price – bullish indicator.
•MACD: Crossed positive with rising histogram, suggesting fresh upward power.
•RSI(14): At 59, healthy but not yet overbought, signaling trend strength.
•Support: ₹865–₹870 first zone, ₹840 strong base; Resistance: ₹915–₹940 immediate, ₹955–₹970 stretch targets.
•Volume and sentiment favor buyers; if ₹870 sustains, structure is positive, otherwise risk of pullback increases.
Result Trend & Future Outlook
•Q1 & Q2 FY26 results reflect a sharp rebound in profit and margin expansion, led by operational leverage and specialty pipeline.
•Management is targeting 50%
$REVENUE share from high-margin CDMO and innovative therapies by 2027; capex guidance indicates aggressive scaling.
•Improved mix, operational efficiency, and asset utilization raise FY27E margin/income projections, but premium valuation requires sustained delivery.
•Near term, any new international contract/joint venture or USFDA approval can act as sentiment boosters; conversely, adverse regulatory/currency moves could trigger volatility.
Entry, Target, and Risk Management
•Buy on
$DIPS between ₹870–₹900, keeping a closing stop loss at ₹840.
•Short-term targets: ₹915 & ₹940. On breakout and strength, look for ₹955–₹970.
•
$LONG-term holders may use corrections to accumulate, subject to fundamental strength and macro cues.
•The uptrend will be valid as long as ₹870 support holds; break below this can invite profit booking.
Risks & Upcoming Events
•Sustained performance in CDMO/biotech and regulatory approvals are key.
•Any delay in global orders,
$NEGATIVE audit outcomes, or unfavorable currency/cost swings are key watchpoints.
•Multiple R&D pipeline events and global launches ahead.
Result Announcement & its Impact:
$LAURUSLABS.NSE Labs will be announcing its quarterly financial results on 23rd October 2025. This result will be closely watched by investors and analysts for updates on revenue growth, margin expansion, new product launches, and any management commentary regarding future outlook, pipeline progress, and global contracts.
Key Impact for Investors:
•The upcoming result will indicate how
$LAURUS Labs is executing on its specialty API and CDMO expansion, as well as whether recent margin and profit growth trends are being sustained.
•Short-term price volatility is expected around the result date, especially if reported numbers differ from market earnings forecasts.
•Positive surprises on earnings, margins, or new contracts could support fresh upside, while disappointments could trigger correction or profit booking.
This scheduled result is a
$CRITICAL event and could dictate the next leg of price movement for Laurus Labs—remain updated for the 23rd October earnings release and assess entry/exit moves accordingly.
Disclaimer & Disclosure
This content is for informational/educational purposes only and does not constitute investment or trading advice. Investing in securities carries risk; always consult your SEBI-registered advisor. Neither author nor Investogainer Research hold any position in Laurus Labs.
